First experiences with single-dose treatment of vaginal trichomoniasis with carnidazole (R 25831).

Abstract

The results of treating 152 women with carnidazole, a new trichomonacidal drug are reported. They were divided into 2 groups. The 1st comprised 91 patients who were treated with 2 g, while the 2nd group comprised 61 patients who were treated with 1.5 g carnidazole in a single oral dose. Defaulter rates were 6.6% for the 1st group and 13.1% for the 2nd. Of the remaining 85 patients in the 1st group, 76(89.5%) were negative at the 1st follow-up 1-3 wk after treatment, 3 (3.5%) were considered to be treatment failures and 6 (7.0%) were considered to be reinfected. Of 53 women treated with 1.5 g, 39 (73.6%) were negative at 1st follow-up, 8 (15.1%) were considered to be treatment failures, and 6 (11.3%) were considered to be reinfected. The difference between the number of patients cured in both groups is statistically significant. Fourteen patients experienced side-effects, but these were of little significance. Carnidazole given in a single oral dose of 2 g in 16 women did not cause consistent changes in any of the hematological and biochemical parameters studied.